Jenny Seligmann, Professor of Gastrointestinal Oncology at University of Leeds, shared a post on LinkedIn:
“Proud to present combined NICHE2 + FOXTROT analysis at ESMO25
In summary
- IO superior to chemo (pre or post surgery)
- Little role of chemo in dMMR CC (!ATOMIC)
- CT staging identified high risk pt
- 20% recurrence in “good prognosis” pts relevant with effective rx!
- Further data to support neoadjuvant IO for routine use! ESP for T4 pts
- Privilege to work with super NKI team.”
More insights from Jenny Seligmann.
